Vasopeptides pp 399-408 | Cite as

A Structure-Activity Basis for Vasotropic Peptide Therapy in Shock

  • Burton M. Altura
  • S. G. Hershey
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 21)

Abstract

Chemical analogues which enhance one or several biologic properties of important naturally occurring substances are regularly sought. Currently in this regard, there is intense interest in developing such analogues of the neurohypophyseal hormones (NHPH), oxytocin and vasopressin. Several which have recently been synthesized not only offer the possibility of increased insight into structure-activity relationships but also may provide for more precise therapeutic drug actions (17).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    B.M. Altura, “Differential actions of polypeptides and other drugs on coronary inflow vessels,” Am. Heart J., 72: 709–711, 1966.PubMedCrossRefGoogle Scholar
  2. 2.
    B.M. Altura, “Evaluation of neurohumoral substances in local regulation of blood flow,” Am. J. Physiol., 212: 1447–1454, 1967.PubMedGoogle Scholar
  3. 3.
    B.M. Altura, “Significance of amino acid residues in vasopressin on contraction in vascular muscle,” Am. J. Physiol., 219: 222–229, 1970.PubMedGoogle Scholar
  4. 4.
    B.M. Altura, “Influence of magnesium and cysteine on vasopressininduced contractions in various canine blood vessels,” Experientia, 26: 1089–1090, 1970.PubMedCrossRefGoogle Scholar
  5. 5.
    B.M. Altura, “Pharmacology of neurohypophyseal hormones and analogs on isolated vascular muscle and in the terminal vascular bed,” in: J.A. Bevan, R.F. Furchgott, R.A. Maxwell and A.P. Som I yo, Eds., Physiology and Pharmacology of Vascular Neuroeffector Systems. Basel, Karger, pp. 274–290, 1971.Google Scholar
  6. 6.
    B.M. Altura, “Chemical and humoral regulation of blood flow through the precapillary sphincter,” Microvascular Res., 3: October, 1971 (in press).Google Scholar
  7. 7.
    B.M. Altura, “Structure-activity relationships of neurohypophyseal polypeptides on different types of isolated mammalian blood vessels,” in: These Proceedings.Google Scholar
  8. 8.
    B.M. Altura and S.G. Hershey, “Pharmacology of neurohypophyseal hormones and their synthetic analogues in the terminal vascular bed. Structure-activity relationships,” Angiology, 18: 428–439, 1967.PubMedCrossRefGoogle Scholar
  9. 9.
    B.M. Altura and S.G. Hershey, “Use of reticuloendothelial phagocytic function as an index in shock therapy,” Bull. N.Y. Acad. Med., 43: 259–266, 1967.PubMedGoogle Scholar
  10. 10.
    B.M. Altura and S.G. Hershey, “Structure-activity relationships of neurohypophyseal polypeptides in the microcirculation: A molecular basis for shock therapy,” in: B. Schildt and L. Thorén, Eds., Intermedes Proceedings 1968: Combined Injuries and Shock. Stockholm, Almqvist and Wiksell, pp. 247–259, 1968.Google Scholar
  11. 11.
    B.M. Altura and S.G. Hershey, “Influence of vasopressor drugs on reticuloendothelial phagocytic function in experimental shock,” in: B. Schildt and L. Thorén, Eds., Intermedes Proceedings 1968: Combined Injuries and Shock. Stockholm, Almqvist and Wiksell, p. 185–193, 1968.Google Scholar
  12. 12.
    B.M. Altura and S.G. Hershey, “Structure-action relationships of vasopressin analogs in the microcirculation and their use in the treatment of experimental shock,” Federation Proc., 29: 711, 1970.Google Scholar
  13. 13.
    B.M. Altura, S.G. Hershey and B.T. Altura, “Microcirculatory actions of polypeptides and their use in the treatment of experimental shock,” Adv. Exptl. Med. Biol., 8: 239–247, 1970.Google Scholar
  14. 14.
    B.M. Altura, S.G. Hershey and V.D.B. Mazzia, “Microcirculatory approach to vasopressor therapy in intestinal ischemic (SMA) shock,” Am. J. Surgery, 111: 186–192, 1966.CrossRefGoogle Scholar
  15. 15.
    B.M. Altura, S.G. Hershey and B.W. Zweifach, “Effects of a synthetic analogue of vasopressin on vascular smooth muscle,” Proc. Soc. Exptl. Biol. Med., 119: 258–261, 1965.Google Scholar
  16. 16.
    B.M. Altura, R. Hsu, V.D.B. Mazzia and S.G. Hershey, “Influence of vasopressors on survival after traumatic, intestinal ischemia and endotoxin shock in rats,” Proc. Soc. Exptl. Biol. Med., 119: 389393, 1965.Google Scholar
  17. 17.
    B. Berde, Ed., “Handbook of Experimental Pharmacology, vol. 23: Neurohypophysial Hormones and Similar Polypeptides.” Berlin, Springer-Verlag, 1968.Google Scholar
  18. 18.
    B. Berde and R.A. Boissonnas, “Basic pharmacological properties of synthetic analogues and homologues of the neurohypophysial hormones,” in: B. Berde, Ed., Handbook of Experimental Pharmacology, vol. 23: Neurohypophysial Hormones and Similar Polypeptides. Berlin, Springer-Verlag, pp. 802–870, 1968.Google Scholar
  19. 19.
    B. Berde, R.A. Boissonnas, R. Huguenin and E. StUrmer, “Vasopressin analogues with selective pressor activity,” Experientia, 20: 42–44, 1964.PubMedCrossRefGoogle Scholar
  20. 20.
    P. Brazeau, “Agents affecting the renal conservation of water,” in: L.S. Goodman and A. Gilman, Eds., The Pharmacological Basis of Therapeutics. New York, Macmillan, pp. 874–885, 1970.Google Scholar
  21. 21.
    J.N. Cohn, F.E. Tristani and I.M. Khatri, “Systemic vasoconstrictor and renal vasodilator effects of PLV-2 (Octapressin) in man,” Circulation, 38: 151–157, 1968.PubMedGoogle Scholar
  22. 22.
    S.G. Hershey and B.M. Altura, “Behandlung des Schocks durch Beeinflussung der peripheren Zirkulation mit vasoaktiven Wirkstoffen: eine mikrozirkulatorische Basis für die Therapie,” Schweiz. Med. Wschr. 96: 1467–1471, 1516–1522, 1966 (2 parts).Google Scholar
  23. 23.
    S.G. Hershey, B.M. Altura and L.R. Orkin, “Therapy of intestinal ischemic (SMA) shock with vasoactive drugs,” Anesthesiology, 29: 466471, 1968.Google Scholar
  24. 24.
    S.G. Hershey, V.D.B. Mazzia, B.M. Altura and L. Gyure, “Effects of vasopressors on the microcirculation and on survival in hemorrhagic shock,” Anesthesiology, 26: 179–189, 1965.PubMedCrossRefGoogle Scholar
  25. 25.
    M.E. Hunter and R.A. Gordon, “Laboratory and clinical studies of 2phenylalanine-8-lysine vasopressin (Octapressin),” Canad. Anaesth. Soc. J., 13: 40–45, 1966.PubMedCrossRefGoogle Scholar
  26. 26.
    R.L. Katz, “Epinephrine and PLV-2: Cardiac rhythm and local vasoconstrictor effects,” Anesthesiology, 26: 619–623, 1965.PubMedCrossRefGoogle Scholar
  27. 27.
    R.L. Katz and G.J. Katz, “Surgical infiltration of pressor drugs and their interaction with volatile anesthetics,” Brit. J. Anaesth., 38: 712–718, 1966.PubMedCrossRefGoogle Scholar
  28. 28.
    O.V. Nielsen and N. Valentin, “Ornithine-8-vasopressin, a new vasoconstrictor used for haemostasis during operation for genital prolapse,” Acta Obstet. Gynec. Scand., 49: 45–48, 1970.CrossRefGoogle Scholar
  29. 29.
    K. Saameli, “The circulatory actions of the neurohypophysial hormones and similar polypeptides.” Berlin, Springer-Verlag, pp. 545–612, 1968.Google Scholar
  30. 30.
    H.B. Ban Dyke, K. Adamsons and S.L. Engel, “Aspects of the biochemistry and physiology of the neurohypophyseal hormones. Recent Progr. Hormone Res., 11: 1–35, 1955.Google Scholar
  31. 31.
    V. du Vigneaud, H.C. Lawler and E.A. Popenoe, “Enzymatic cleavage of glycinamide from vasopressin and a proposed structure for this pressor-antidiuretic hormone of the posterior pituitary,” J.Am. Chem. Soc., 75: 4880–4881, 1953.CrossRefGoogle Scholar
  32. 32.
    V. du Vigneaud, C.H. Ressler, J.M. Swan, C.W. Roberts, P.G. Katsoyannis and S. Gordon, “The synthesis of an octapeptide amide with the hormonal activity of oxytocin.” J. Am. Chem. Soc., 75: 4879–4880, 1953.CrossRefGoogle Scholar
  33. 33.
    B.W. Zweifach, “Functional Behavior of the Microcirculation.” Springfield, C.C. Thomas, 1961.Google Scholar

Copyright information

© Plenum Press, New York 1972

Authors and Affiliations

  • Burton M. Altura
    • 1
  • S. G. Hershey
    • 1
  1. 1.Departments of Anesthesiology and PhysiologyAlbert Einstein College of MedicineBronxUSA

Personalised recommendations